康泰医学(300869) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥126,443,232.77, representing a year-on-year increase of 3.56%[5] - The net profit attributable to shareholders for Q3 2025 was -¥7,537,730.77, a significant decrease of 534.25% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥15,850,705.00, down 508.87% year-on-year[5] - The basic earnings per share for Q3 2025 was -¥0.0188, reflecting a decline of 537.21% compared to the previous year[5] - The net profit for the current period is 9,399,842.40, a decrease of 5.07% compared to 9,902,927.86 from the previous period[21] - The total profit for the current period is 10,110,924.14, down 9.38% from 11,158,450.98 in the previous period[21] - The operating profit for the current period is 10,077,737.15, slightly down from 10,472,484.72 in the previous period[21] - The basic and diluted earnings per share for the current period are both 0.0234, down from 0.0246 in the previous period[21] Assets and Liabilities - The total assets at the end of Q3 2025 amounted to ¥2,790,885,467.87, an increase of 2.40% from the end of the previous year[5] - Total assets increased to ¥2,790,885,467.87 from ¥2,725,517,187.03, marking a growth of 2.40%[18] - Total liabilities rose to ¥1,024,759,499.30 from ¥868,101,437.11, reflecting an increase of 18.06%[18] - The company's total equity decreased to ¥1,766,125,968.57 from ¥1,857,415,749.92, a decline of 4.90%[18] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥19,600,893.57, down 44.30% from the previous year[5] - Cash flow from operating activities for the current period is 19,600,893.57, a decrease of 44.5% compared to 35,193,005.23 from the previous period[22] - Cash flow from investing activities shows a net inflow of 34,205,511.05, down from 408,315,248.82 in the previous period[22] - Cash flow from financing activities has a net inflow of 46,737,425.10, compared to a net outflow of 386,682,802.77 in the previous period[23] - The total cash and cash equivalents at the end of the period is 777,858,965.40, an increase from 518,573,031.87 at the end of the previous period[23] Expenses - The company reported a significant increase in sales expenses, which contributed to the decline in net profit[8] - Total operating costs decreased to ¥335,255,538.73 from ¥336,662,644.47, reflecting a reduction of 0.42%[20] - Operating costs specifically for goods sold were ¥155,727,261.42, down from ¥167,266,311.47, indicating a decrease of 6.93%[20] - Research and development expenses amounted to ¥69,070,735.32, a decrease of 17.25% from ¥83,429,418.51 in the previous period[20] - The company reported a financial expense of -¥2,245,863.34, an improvement compared to -¥3,681,104.46 in the previous period[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,665[10] - The number of restricted shares held by top executives decreased from 150,233,733 to 148,441,983, with a total of 1,791,750 shares released from restrictions during the period[13] Government Support - The company received government subsidies amounting to ¥3,536,523.42 during the reporting period[6] Other Comprehensive Income - The company reported a decrease in other comprehensive income after tax to -245,172.40 from -713,854.79 in the previous period[21] Sales Performance - Cash inflow from sales of goods and services is 361,874,584.12, an increase from 344,951,997.27 in the previous period[22]